AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9972758 — intervention group
Group type: COMPARATOR
Intervention: Epidural steroids administered without fluoroscopic guidance
Number of subjects: 50
Study 7593780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 0
Study 7593780 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 0
Study 7593780 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0
Study 7593780 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐adenosylmethionine
Number of subjects: 0
Study 7593780 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0
Study 7593780 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 7593780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2332096 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile glucagon delivery (377 ng/min for 2 min followed by 11 min with no infusion)
Number of subjects: 7
Study 2332096 — intervention group
Group type: COMPARATOR
Intervention: Continuous glucagon delivery (58 ng/min)
Number of subjects: 7
Study 2332096 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile glucagon delivery
Number of subjects: 7
Study 2332096 — intervention group
Group type: COMPARATOR
Intervention: Continuous glucagon delivery
Number of subjects: 7
Study 6996158 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of penicillins, probenecid, a sulphonamide and ornidazole (once-only administration)
Number of subjects: 60
Study 6996158 — intervention group
Group type: COMPARATOR
Intervention: Combination of penicillins, probenecid, a sulphonamide and metronidazole
Number of subjects: 60
Study 31564585 — intervention group
Group type: COMPARATOR
Intervention: Medical intervention alone
Number of subjects: 0
Study 31564585 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 31564585 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty/stenting (CAS)
Number of subjects: 0
Study 31564585 — intervention group
Group type: COMPARATOR
Intervention: Current optimal medical intervention
Number of subjects: 0
Study 30788788 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Strand Assembly (SSA) methods for combinatorial pathway engineering; details on dosage and duration not available.
Number of subjects: 0
Study 30788788 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinatorial multigene pathway assembly scheme based on SSA and Golden Gate Assembly; details on dosage and duration not available.
Number of subjects: 0
Study 28705783 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback intervention
Number of subjects: 48
Study 28705783 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral simethicone)
Number of subjects: 48
Study 25880946 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hepatitis B vaccination schedule (0-1-2 months)
Number of subjects: 707
Study 25880946 — intervention group
Group type: COMPARATOR
Intervention: Standard hepatitis B vaccination schedule (0-1-6 months)
Number of subjects: 707
Study 23652196 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure patching with ofloxacin ointment (patch group, PG)
Number of subjects: 66
Study 23652196 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic contact lens with ofloxacin eye drops (contact lens group, CLG)
Number of subjects: 66
Study 23652196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin ointment alone (ointment group, OG)
Number of subjects: 66
Study 21333698 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomniacs
Number of subjects: 16
Study 21333698 — intervention group
Group type: COMPARATOR
Intervention: Good sleepers
Number of subjects: 16
Study 19479644 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 31
Study 19479644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 31
Study 17602156 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide
Number of subjects: 0
Study 16299544 — intervention group
Group type: COMPARATOR
Intervention: Hematopoietic stem cell transplantation (HSCT)
Number of subjects: 306
Study 12716667 — intervention group
Group type: EXPERIMENTAL
Intervention: Large portion of an entrée
Number of subjects: 30
Study 12716667 — intervention group
Group type: COMPARATOR
Intervention: Age-appropriate portion of an entrée
Number of subjects: 30
Study 10569329 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pravastatin/day
Number of subjects: 5804
Study 10569329 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5804
Study 8915127 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms subcutaneously every 8 hours for a maximum of six doses)
Number of subjects: 33
Study 8915127 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment with intravenous fluid replacement and antibiotic treatment)
Number of subjects: 33
Study 8915127 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 33
Study 8915127 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study 1861552 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy
Number of subjects: 0
Study 1861552 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 1861552 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant therapy
Number of subjects: 0
Study 6882062 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel, single oral dose of 30 mg kg‐1
Number of subjects: 0
Study 6882062 — intervention group
Group type: COMPARATOR
Intervention: Niridazole
Number of subjects: 0
Study 6882062 — intervention group
Group type: COMPARATOR
Intervention: Metrifonate
Number of subjects: 0
Study 31084635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Interpersonal Therapy (DIT), 16 sessions over approximately 5 months
Number of subjects: 147
Study 31084635 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Treatment (LIT), control intervention
Number of subjects: 147
Study 31084635 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioural Therapy (CBT)
Number of subjects: 147
Study 31084635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Interpersonal Therapy (DIT)
Number of subjects: 147
Study 31868699 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromechanically-assisted gait training (EAGT) using the Hybrid Assistive Limb (HAL)
Number of subjects: 0
Study 31868699 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 0
Study 28179351 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus S-1 chemotherapy
Number of subjects: 38
Study 24658148 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle technique with autograft (DB-AU)
Number of subjects: 424
Study 24658148 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle technique with allograft (DB-AL)
Number of subjects: 424
Study 24658148 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle technique with allograft (SB)
Number of subjects: 424
Study 23783025 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified human milk (HM)
Number of subjects: 38
Study 23783025 — intervention group
Group type: COMPARATOR
Intervention: Preterm infant formula
Number of subjects: 38
Study 21744314 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 466
Study 21744314 — intervention group
Group type: COMPARATOR
Intervention: Control (no tirofiban)
Number of subjects: 466
Study 19491035 — intervention group
Group type: EXPERIMENTAL
Intervention: Biorelevant dissolution tests under simulated pre- and postprandial conditions
Number of subjects: 16
Study 19491035 — intervention group
Group type: COMPARATOR
Intervention: Compendial dissolution tests using USP Apparatus 1 and 2
Number of subjects: 16
Study 19491035 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo administration of diclofenac sodium pellets
Number of subjects: 16
Study 16307008 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 24
Study 16307008 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg + Tadalafil 20 mg
Number of subjects: 24
Study 16307008 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg + Sildenafil 100 mg
Number of subjects: 24
Study 16307008 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 20 mg
Number of subjects: 24
Study 16307008 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 100 mg
Number of subjects: 24
Study 15315647 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste + AmF/SnF2 mouthrinse
Number of subjects: 42
Study 15315647 — intervention group
Group type: COMPARATOR
Intervention: AmF/SnF2 toothpaste only
Number of subjects: 42
Study 10903223 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular use of albuterol
Number of subjects: 190
Study 10903223 — intervention group
Group type: COMPARATOR
Intervention: As-needed use of albuterol
Number of subjects: 190
Study 9068463 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg for 4 weeks followed by either lansoprazole 30 mg or 60 mg for another 4 weeks
Number of subjects: 159
Study 9068463 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 159
Study 9068463 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.i.d. for 8 weeks
Number of subjects: 159
Study 9068463 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 159
Study 8438610 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunization with cholera toxin B-subunit
Number of subjects: 0
Study 8438610 — intervention group
Group type: COMPARATOR
Intervention: Naive volunteers before immunization
Number of subjects: 0
Study 3101242 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron dextran (3 ml intramuscular iron dextran)
Number of subjects: 0
Study 3101242 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 3101242 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron dextran
Number of subjects: 0
Study 30049223 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg of inhaled vaporized cannabis (18.2% Δ9‐tetrahydrocannabinol, <0.1% cannabidiol)
Number of subjects: 16
Study 30049223 — intervention group
Group type: COMPARATOR
Intervention: 35 mg of placebo control cannabis (CTRL; 0.33% Δ9‐tetrahydrocannabinol, <0.99% cannabidiol)
Number of subjects: 16
Study 27684609 — intervention group
Group type: EXPERIMENTAL
Intervention: Body scan meditation
Number of subjects: 53
Study 27684609 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 53
Study 25662353 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 992
Study 23795576 — intervention group
Group type: EXPERIMENTAL
Intervention: VAL/HCT fixed-dose combination (FDC) tablet
Number of subjects: 48
Study 23795576 — intervention group
Group type: EXPERIMENTAL
Intervention: VAL + HCT (concomitant administration)
Number of subjects: 48
Study 23795576 — intervention group
Group type: COMPARATOR
Intervention: VAL alone
Number of subjects: 48
Study 23795576 — intervention group
Group type: COMPARATOR
Intervention: HCT alone
Number of subjects: 48
Study 21091293 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g chicory native inulin
Number of subjects: 25
Study 21091293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 18364345 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-administered measures
Number of subjects: 319
Study 18364345 — intervention group
Group type: COMPARATOR
Intervention: Telephone-administered measures
Number of subjects: 319
Study 16263174 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of latanoprost and timolol once daily in the evening
Number of subjects: 517
Study 16263174 — intervention group
Group type: COMPARATOR
Intervention: Unfixed combination of latanoprost once daily in the evening and timolol in the morning and evening
Number of subjects: 517
Study 14618044 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 220
Study 14618044 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (4/5 day preoperative regimen)
Number of subjects: 220
Study 14618044 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (1-day preoperative regimen)
Number of subjects: 220
Study 14618044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 12607634 — intervention group
Group type: EXPERIMENTAL
Intervention: S + R (surgery plus radiotherapy)
Number of subjects: 495
Study 12607634 — intervention group
Group type: COMPARATOR
Intervention: S (surgery alone)
Number of subjects: 495
Study 10576171 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 1 treatment
Number of subjects: 242
Study 10576171 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phase 1 treatment)
Number of subjects: 242
Study 8726552 — intervention group
Group type: EXPERIMENTAL
Intervention: Coital experience among girls (52.3%)
Number of subjects: 920
Study 8726552 — intervention group
Group type: EXPERIMENTAL
Intervention: Coital experience among boys (41.4%)
Number of subjects: 920
Study 8726552 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for most recent intercourse among boys
Number of subjects: 920
Study 8726552 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for first sexual intercourse among both genders
Number of subjects: 920
Study 2010577 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine iron supplementation
Number of subjects: 2912
Study 2010577 — intervention group
Group type: COMPARATOR
Intervention: Selective iron supplementation
Number of subjects: 2912
Study 6306711 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (300 mg)
Number of subjects: 6
Study 6306711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30608440 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 320
Study 30608440 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir (TDF)
Number of subjects: 320
Study 30608440 — intervention group
Group type: COMPARATOR
Intervention: Both ETV and TDF
Number of subjects: 320
Study 30261680 — intervention group
Group type: EXPERIMENTAL
Intervention: MLT-enriched red wine (MLT+)
Number of subjects: 12
Study 30261680 — intervention group
Group type: COMPARATOR
Intervention: Placebo red wine (PLC)
Number of subjects: 12
Study 26894169 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (1 ml of 10,000 Kallikrein Inactivator Units sub‐mucosally injected)
Number of subjects: 30
Study 26894169 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (1 ml injected as control)
Number of subjects: 30
Study 24245554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 0.03 mg/drospirenone (group 1)
Number of subjects: 60
Study 24245554 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructus agni casti (group 2)
Number of subjects: 60
Study 24245554 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 60
Study 24469928 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy (MCT)
Number of subjects: 20
Study 24469928 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control
Number of subjects: 20
Study 21146657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 12092
Study 17430320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative pain threshold measured using Pain Matcher (PM)
Number of subjects: 39
Study 17430320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative PM assessment of sensory threshold
Number of subjects: 39
Study 15774256 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-89 (immunotherapeutic); 1 capsule per day for 90 days, followed by 3 months without treatment, then 10 days in Months 7, 8, and 9.
Number of subjects: 453
Study 15774256 — intervention group
Group type: COMPARATOR
Intervention: Placebo; 1 capsule per day for 90 days, followed by 3 months without treatment, then 10 days in Months 7, 8, and 9.
Number of subjects: 453
Study 12200644 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Osteocare device (active group)
Number of subjects: 157
Study 12200644 — intervention group
Group type: COMPARATOR
Intervention: Sham group (performed similar motion without triggering impact force)
Number of subjects: 157
Study 12200644 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prescribed heel drop exercise)
Number of subjects: 157
Study 10099066 — intervention group
Group type: EXPERIMENTAL
Intervention: Claritin‐D 24 Hour (loratadine 10 mg and pseudoephedrine sulfate 240 mg)
Number of subjects: 469
Study 10099066 — intervention group
Group type: EXPERIMENTAL
Intervention: Claritin‐D 12 Hour (loratadine 5 mg and pseudoephedrine sulfate 120 mg)
Number of subjects: 469
Study 10099066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study 7654944 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 0
Study 7654944 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonexercise)
Number of subjects: 0
Study 2568776 — intervention group
Group type: EXPERIMENTAL
Intervention: iopromide
Number of subjects: 100
Study 2568776 — intervention group
Group type: COMPARATOR
Intervention: iohexol
Number of subjects: 100
Study 341283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferastral (iron-poly (sorbitol-gluconic acid) complex)
Number of subjects: 38
Study 341283 — intervention group
Group type: COMPARATOR
Intervention: Iron-dextran (Total Dose Infusion)
Number of subjects: 38
Study 29702630 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based VR canoe paddling training for 30 minutes each day, three times per week, for five weeks
Number of subjects: 30
Study 29702630 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation program
Number of subjects: 30
Study 28061841 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week preoperative supervised neuromuscular exercise program
Number of subjects: 165
Study 28061841 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative exercise)
Number of subjects: 165
Study 26194125 — intervention group
Group type: EXPERIMENTAL
Intervention: Benachio Q solution®
Number of subjects: 20
Study 26194125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23040887 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (750 mg)
Number of subjects: 78
Study 21914196 — intervention group
Group type: EXPERIMENTAL
Intervention: K-wire fixation
Number of subjects: 390
Study 21914196 — intervention group
Group type: COMPARATOR
Intervention: locking-plate fixation
Number of subjects: 390
Study 18326603 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley or rye kernel breakfasts
Number of subjects: 12
Study 18326603 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley kernel evening meal
Number of subjects: 12
Study 18326603 — intervention group
Group type: COMPARATOR
Intervention: White‐wheat bread
Number of subjects: 12
Study 16599766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional body rocking
Number of subjects: 0
Study 16599766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting postures
Number of subjects: 0
Study 16599766 — intervention group
Group type: COMPARATOR
Intervention: Center of pressure (COP) motion
Number of subjects: 0
Study 12687836 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil, 200 mg/day (n = 14)
Number of subjects: 52
Study 12687836 — intervention group
Group type: COMPARATOR
Intervention: Class Ic antiarrhythmic drugs (Flecainide, 100 to 200 mg/day (n = 15) or Pilsicainide, 75 to 150 mg/day (n = 23))
Number of subjects: 52
Study 12687836 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil
Number of subjects: 52
Study 12687836 — intervention group
Group type: COMPARATOR
Intervention: Class Ic antiarrhythmic drugs
Number of subjects: 52
Study 11423497 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional or intensive glucose control policies
Number of subjects: 2999
Study 9261765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% dapiprazole (1 drop)
Number of subjects: 60
Study 9261765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% dapiprazole (2 drops followed by 2 additional drops 5 minutes later)
Number of subjects: 60
Study 9261765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8388332 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and transcutaneous stimulation (TES)
Number of subjects: 42
Study 8388332 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose fentanyl
Number of subjects: 42
Study 8388332 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acupuncture and TES with moderate-dose fentanyl
Number of subjects: 42
Study 8388332 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture and TES
Number of subjects: 42
Study 3812308 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (mean 371 mg)
Number of subjects: 21
Study 3812308 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (mean 307 mg)
Number of subjects: 21
Study 3812308 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 21
Study 3812308 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 21
Study 2774228 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms/kg (group B)
Number of subjects: 55
Study 2774228 — intervention group
Group type: COMPARATOR
Intervention: Placebo lollipop (group C)
Number of subjects: 55
Study 2774228 — intervention group
Group type: COMPARATOR
Intervention: No premedication (group A)
Number of subjects: 55
Study 2774228 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) (group B)
Number of subjects: 55
Study 30641827 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia
Number of subjects: 120
Study 30641827 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia plus dyslipidemia
Number of subjects: 120
Study 30641827 — intervention group
Group type: COMPARATOR
Intervention: Control (normoglycemia and normolipidemia)
Number of subjects: 120
Study 30641827 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between hyperglycemia and hyperglycemia plus dyslipidemia
Number of subjects: 120